- Home
- TRNR vs MTVA Comparison
TRNR vs MTVA Comparison
Compare TRNR & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRNR
- MTVA
- Stock Information
- Founded
- TRNR 2017
- MTVA 2014
- Country
- TRNR United States
- MTVA United States
- Employees
- TRNR N/A
- MTVA N/A
- Industry
- TRNR Consumer Electronics/Appliances
- MTVA
- Sector
- TRNR Technology
- MTVA
- Exchange
- TRNR Nasdaq
- MTVA NYSE
- Market Cap
- TRNR 6.8M
- MTVA 7.1M
- IPO Year
- TRNR 2023
- MTVA N/A
- Fundamental
- Price
- TRNR $0.79
- MTVA $0.70
- Analyst Decision
- TRNR
- MTVA Strong Buy
- Analyst Count
- TRNR 0
- MTVA 1
- Target Price
- TRNR N/A
- MTVA $12.00
- AVG Volume (30 Days)
- TRNR 1.7M
- MTVA 1.5M
- Earning Date
- TRNR 05-19-2025
- MTVA 05-20-2025
- Dividend Yield
- TRNR N/A
- MTVA N/A
- EPS Growth
- TRNR N/A
- MTVA N/A
- EPS
- TRNR N/A
- MTVA N/A
- Revenue
- TRNR $5,380,000.00
- MTVA N/A
- Revenue This Year
- TRNR $355.02
- MTVA N/A
- Revenue Next Year
- TRNR N/A
- MTVA N/A
- P/E Ratio
- TRNR N/A
- MTVA N/A
- Revenue Growth
- TRNR 459.25
- MTVA N/A
- 52 Week Low
- TRNR $0.62
- MTVA $0.71
- 52 Week High
- TRNR $996.00
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- TRNR 47.02
- MTVA N/A
- Support Level
- TRNR $0.56
- MTVA N/A
- Resistance Level
- TRNR $0.74
- MTVA N/A
- Average True Range (ATR)
- TRNR 0.08
- MTVA 0.00
- MACD
- TRNR 0.03
- MTVA 0.00
- Stochastic Oscillator
- TRNR 76.69
- MTVA 0.00
About TRNR Interactive Strength Inc.
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.